Navigation Links
Wyeth Names Michael Kamarck President, Technical Operations & Product Supply
Date:11/20/2008

MADISON, N.J., Nov. 20 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE) today announced that Michael Kamarck, Ph.D., 57, has been promoted to President, Technical Operations & Product Supply (TO&PS). Dr. Kamarck will be responsible for all aspects of technical operations and product supply for Wyeth, including its Pharmaceutical, BioPharma, Vaccine, Consumer Healthcare and Nutritional units. He succeeds Charles Portwood, 58, who has been appointed to the new role of Executive Vice President, TO&PS Operational Excellence. Both positions will report to Joseph Mahady, President, Wyeth Pharmaceuticals.

"Dr. Kamarck brings strong leadership as well as superb technical and scientific skills to this critical role. He will continue the transformation of our TO&PS organization as we supply medicines of exceptional quality to our customers and patients," says Mr. Mahady.

He joined Wyeth in 2001 and over the next six years successfully led the expansion of Wyeth's global biotechnology manufacturing network. In 2007, Dr. Kamarck was promoted to Executive Vice President, TO&PS where he was responsible for biotechnology and pharmaceutical operations at 13 international sites and for process development of the late-stage pipeline.

Dr. Kamarck began his career in biotechnology and pharmaceutical research for Bayer AG. Before joining Wyeth, he was promoted to Senior Vice President of Operations for the newly formed Bayer Biologicals.

He graduated from Oberlin College and received his Ph.D. in Biochemistry from the Massachusetts Institute of Technology. From 1979 to 1982, Dr. Kamarck was a Fellow of the Leukemia Society of America at Yale University. He is the author of more than 50 peer-reviewed publications and eight issued patents.

Mr. Portwood joined Wyeth in 2001 as President, Global Supply Chain, Wyeth Pharmaceuticals. Through his experience and leadership, he has guided a major transformation of the TO&PS organization.

"Charlie has taken our TO&PS organization to a whole new level of competency and performance," says Mr. Mahady. "He has been instrumental in creating this succession plan and in building a depth of talent in the TO&PS leadership team. We are pleased he will remain an integral part of the Wyeth organization. We are counting on him to support improvement and standardization efforts across the Wyeth manufacturing network."

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.


'/>"/>
SOURCE Wyeth
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Wyeth Declares Preferred Stock Dividend
2. Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months
3. Wyeth Wins Philadelphia Diet Drug Trial Involving Claim of PPH
4. Wyeth Announces Increase in Common Stock Dividend
5. Retrospective Analysis of Phase 3 Data Suggest Wyeths Investigational Compound Bazedoxifene/Conjugated Estrogens Comparable to Placebo on Incidence of Abnormal Mammograms
6. Wyeth Sets Webcast And Conference Call for 2008 Third Quarter Earnings
7. Cyprus and Ireland Add Wyeths 7-Valent Pneumococcal Conjugate Vaccine (PCV7) to Their National Immunisation Schedules
8. Wyeth Names Daniel J. McIntyre Vice President, Corporate Communications
9. Wyeth and Impax Announce Final Settlement of Effexor XR Patent Suit
10. Wyeths Motion to Overturn Punitive Damages Award Granted by Arkansas Court
11. Wyeth Announces Bernard Poussot Assumes Chairman of the Board Position
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and Mold) microbial test has received AOAC Research Institute approval 061601. , “This ... introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... ... 23, 2016 , ... In a new case report published today in STEM ... who developed lymphedema after being treated for breast cancer benefitted from an injection of ... dealing with this debilitating, frequent side effect of cancer treatment. , Lymphedema ...
Breaking Biology Technology:
(Date:6/20/2016)... DALLAS , June 20, 2016 ... criminal justice technology solutions for public safety, investigation, ... by the prisons involved, it has secured the ... Corrections (DOC) facilities for Managed Access Systems (MAS) ... (4) additional facilities to be installed by October, ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/1/2016)... Favorable Government Initiatives Coupled With ... Identification to Boost Global Biometrics System Market Through 2021  ... report, " Global Biometrics Market By Type, By ... 2011 - 2021", the global biometrics market is projected ... of growing security concerns across various end use sectors ...
Breaking Biology News(10 mins):